Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow HilleVax, Inc.

Get SEC filing alerts via email and in your feed for HilleVax, Inc.

HLVX

HilleVax, Inc.

About HilleVax, Inc.

HilleVax is a biopharmaceutical company developing novel vaccines, primarily targeting norovirus-induced gastroenteritis. Its lead candidate, HIL-214, is a VLP-based vaccine designed to prevent severe AGE caused by norovirus, with ongoing clinical trials in adults and infants. The company leverages proprietary VLP technology, focusing on high-risk populations like children and older adults, aiming to address a global, underserved market with significant health and economic burdens.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from HilleVax, Inc.

1
1
HilleVax, Inc. HilleVax Reports $5.3M Net Loss, Significant Expense Reductions in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
HilleVax, Inc. HilleVax Reports Reduced Losses and Strategic License Agreement for Norovirus Vaccine

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
HilleVax, Inc. HilleVax Reports $147.3 Million Net Loss for 2024, Driven by Increased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
HilleVax, Inc. HilleVax Reports Decrease in Cash and Cash Equivalents, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments